Sign up for our daily briefing

Make your busy days simpler with the Axios AM and PM newsletters. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to the Axios Closer newsletter for insights into the day’s business news and trends and why they matter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with the Axios Sports newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with the Axios Des Moines newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with the Axios Tampa Bay newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Aïda Amer/Axios

The rapid spread of the Delta variant around the rich world has injected increased urgency into the debate around booster shots, but the World Health Organization and public health experts are trying to keep the focus on getting vaccines to those who don’t yet have access.

Why it matters: Israel last week became the first country to offer boosters to people with weak immune systems, and Pfizer is pushing for rapid approval of boosters in the U.S., citing preliminary data that suggests immunity may begin to wane after six months.

Yes, but: Those findings conflict with other data, and scientists and regulators say it’s too early to know whether boosters will be needed.

  • Still, wealthy countries like the U.S., U.K. and South Korea have already placed bulk orders to hedge against the need for boosters. Countries that might otherwise donate surplus doses also have an incentive to hold onto them.
  • “I think we’re definitely moving toward boosters being deployed across most high-income countries for some high-risk populations over the next three to six months,” says Krishna Udayakumar, director of Duke University’s Global Health Innovation Center.

But the debate around boosters in rich countries is happening with just a fraction of people in the developing world having had a single shot, including just 3% across Africa.

  • WHO director-general Tedros Adhanom Ghebreyesus has accused companies like Pfizer and Moderna — which stand to profit more from boosters for rich countries than first doses for poorer ones — of “making conscious choices right now not to protect those in most need.”
  • Warning against a "two-track pandemic," he urged companies and countries to share doses with the COVAX facility rather than save them for boosters.
  • The WHO’s chief scientist, Soumya Swaminathan, has said there’s no evidence that booster shots will be needed before “a year or two years," if at all.

Even if immunity does wane over time, people who are vaccinated will still have some protection, meaning it's far more urgent from a global health standpoint to vaccinate those who haven’t had a shot yet — particularly health care workers and vulnerable people in lower-income countries.

  • But even world leaders who frequently cite the need for "equitable access" to vaccines have consistently prioritized protecting their own populations.

New Zealand Prime Minister Jacinda Ardern hedged at a virtual press conference this week when I asked whether it would be wrong for rich countries to give boosters while access remained so uneven.

  • She said the imperative was to increase immunity so as to reduce the risk from variants, and countries would have to make their own decisions as to the role of boosters.

The state of play: In the long term, the cash that countries and companies are pouring into the development of booster shots could ensure a greater overall supply, Udayakumar says.

  • For now, particularly in the next three months while supply remains tight, it’s yet another hurdle for low- and middle-income countries struggling for access, he says.

Go deeper

Updated Oct 26, 2021 - Health

Prime minister flags vaccine mandate for 40% of New Zealand workforce

New Zealand Prime Minister Jacinda Ardern during an October COVID-19 briefing in Wellington, New Zealand. Photo: Robert Kitchin - Pool/Getty Images

New Zealand Prime Minister Jacinda Ardern on Tuesday announced a COVID-19 vaccine mandate for businesses, as the government pushes to reach a nationwide 90% vaccination target.

Why it matters: Under the new COVID-19 Protection Framework, businesses must require vaccine certificates from customers if they're in close contact with them. Ardern said at a briefing Tuesday that such venues wishing to operate, including hair salons, bars, restaurants and gyms, must ensure staff is vaccinated.

Updated 1 hour ago - Politics & Policy

Omicron dashboard

Illustration: Shoshana Gordon/Axios

  1. Health: Fauci: "Confident" Omicron cases will peak in February.
  2. Vaccines: The shifting definition of fully vaccinated.
  3. Politics: New York Supreme Court strikes down Gov. Hochul's mask mandate for public areas — Sarah Palin tests positive for COVID, delaying defamation trial — Virginia school boards sue Gov. Youngkin for lifting mask mandate.
  4. World: U.K. to lift travel testing requirement for fully vaccinated — Beijing Olympic Committee lowers testing threshold ahead of Games.
  5. Variant tracker
Tina Reed, author of Vitals
Oct 26, 2021 - Health

FDA panel endorses Pfizer vaccines for 5-to-11-year-olds

Photo: Justin Sullivan/Getty Images

Members of the Food and Drug Administration's vaccine expert panel Tuesday endorsed a two-dose series of Pfizer-BioNTech's COVID-19 vaccine for children ages 5–11. The final vote was 17 members in favor, with one member abstaining.

Why it matters: While not binding, the decision is a long-awaited step toward getting COVID vaccines in the arms of some of the youngest Americans potentially in time to get many fully vaccinated in advance of the holiday season.